ERBB2 and breast cancer: It is indicated for (i) the treatment of unresectable locally advanced or mTNBC who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease; and (ii) unresectable or metastatic HR‐positive and HER2‐negative breast cancer (HR+/HER2− BC) who have received endocrine‐based therapy, and at least two additional systemic therapies in the advanced setting.12